1/2
May 18 (UPI) — According to recently released data, researchers have discovered that a drug recently approved to treat mpox is highly effective after only two doses.
The Jynneos vaccine, developed by Bavarain Nordic, was originally created to protect against smallpox, a related, more dangerous virus that was declared eradicated in 1980. Due to genetic similarities between the two viruses, it was believed that Jynneos would also provide protection against mpox.
A study conducted by the New York State Department of Health found that two doses of the Jynneos vaccine were over 88% effective as an inoculation.
“While mpox cases have decreased, vaccine coverage remains low, and the duration of protection is still unknown, leaving room for potential mpox outbreaks,” the research revealed.
Human transmission of mpox occurs through exposure to infected bodily fluids, with a possible airborne route. Separate research from the University of Bochum in Germany demonstrated that the virus can survive on surfaces at room temperature for up to 11 days.
Due to the risk associated with bodily fluids, the Centers for Disease Control and Prevention (CDC) stated last year that the majority of mpox infections were among homosexual men, bisexuals, and other men who engage in same-sex intimacy.
A broader study published in the New England Journal of Medicine found that among adults aged 18-49 in high-risk populations across 12 jurisdictions, two doses of the vaccine proved to be 86% effective against mpox.
Last week, the World Health Organization (WHO) declared that mpox was no longer a global health emergency. However, U.S. health officials still urged high-risk individuals who have not been vaccinated for mpox to do so in anticipation of a potential resurgence of the virus in the coming months.
Federal modeling has indicated that a new surge could be worse than the previous year, but only approximately 23% of high-risk individuals have received the mpox vaccine, according to the CDC.
WHO also emphasized that efforts to control the spread of mpox have largely been carried out without significant external funding. Additional support will be crucial in order to successfully eliminate the virus.
The UN-backed agency has chosen to refer to the virus as “mpox” instead of “monkeypox” to prevent the use of racist and stigmatizing language.
Both terms will be used by WHO for one year as the transition from the former term to the latter takes place. The organization is responsible for assigning names to global diseases.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
